Immunosuppression articles from across Nature Portfolio

Immunosuppression is the deliberate prevention or reduction of an immune response. It can result from the administration of immunosuppressive agents or from the deliberate depletion of immune cells, as well as from malnutrition, cancers and certain chronic infections such as HIV. An unwanted side-effect of immunosuppression is immunodeficiency.

Latest Research and Reviews

Reviews | 22 March 2023

Engineering nanomaterial physical characteristics for cancer immunotherapy

Physical properties affect immune signalling and effector functions in distinct immune cell subtypes. This Review discusses the impact of engineering nanomaterial physical characteristics on modulating immune responses and thus promoting efficient and effective cancer immunotherapy.
- DaeYong Lee
- , Kristin Huntoon
- & Wen Jiang
Nature Reviews Bioengineering, 1-19
Research
30 January 2023 | Open Access

Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8⁺ T cells in hepatocellular carcinoma

In vitro and in vivo validation of Cancer Genome Atlas screening results demonstrate that RBPJ is an important factor regulating the function of T cells in hepatocellular carcinoma.
- Banglun Pan
- , Zengbin Wang
- & Nanhong Tang
Communications Biology 6, 123
Research
26 January 2023 | Open Access

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

Glioblastoma (GBM) is characterized by local and systemic immunosuppression, showing limited responses to immunotherapies. Here the authors describe the design of a nanoplatform composed of the lymphopenia alleviating agent cannabidiol and the lymphocyte recruiting cytokine LIGHT, promoting anti-tumor immune responses in GBM preclinical models.
- Songlei Zhou
- , Yukun Huang
- & Jun Chen
Nature Communications 14, 435
Reviews | 25 January 2023

Biomaterials tools to modulate the tumour microenvironment in immunotherapy

The tumour microenvironment of solid tumours can prevent immune cell infiltration and negatively affect the efficacy of immunotherapies. This Review discusses the design of biomaterials-based tools that can modulate the physicochemical features of the tumour microenvironment to assist immunotherapies.
- Yu Chao
- & Zhuang Liu
Nature Reviews Bioengineering 1, 125-138
Research | 28 December 2022

Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells

Ha and colleagues show that loss of PD-1 expression on regulatory T cells in the tumor environment reduces their metabolic fitness and proliferative capacity.
- Myeong Joon Kim
- , Kyungsoo Kim
- & Sang-Jun Ha
Nature Immunology 24, 148-161
Reviews
23 December 2022 | Open Access

Tumour-infiltrating lymphocytes: from prognosis to treatment selection
- Koen Brummel
- , Anneke L. Eerkens
- & Hans W. Nijman
British Journal of Cancer 128, 451-458

All Research & Reviews

News and Comment

News & Views | 13 January 2023

Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer

Modulation of T cell immune checkpoints combined with inhibition of chemokine receptors on myeloid-derived suppressor cells can reprogram the highly suppressive tumor immune microenvironment of pancreatic ductal adenocarcinoma (PDAC), and generates durable complete responses in a PDAC mouse model. These results provide a testable clinical regimen for human PDAC.

Nature Cancer 4, 7-8
Research Highlights | 04 November 2022

Immunosuppression
- Stephanie Houston
Nature Immunology 23, 1520
News & Views | 25 July 2022

Reactivity to type I interferon is key to predict cancer immunotherapy response

The response of circulating effector CD4 T cells to type I interferons (IFN-I) correlates with the overall survival of patients with cancer receiving immune checkpoint inhibition. IFN-I responsiveness is already epigenetically encoded before treatment initiation, highlighting a deterministic, clinically relevant feature that can predict therapeutic efficacy.

Nature Immunology 23, 1146-1147
Editorial | 19 December 2021

Immune regulation in the tumor microenvironment and its relevance in cancer therapy
- Weiping Zou
Cellular & Molecular Immunology 19, 1-2
Comments & Opinion | 19 October 2021

COVID-19 vaccination in patients with immunity-mediated kidney disease

Vaccination against SARS-CoV-2 seems to be safe in patients with immunity-mediated kidney disease, although their immunological responses to vaccination are impaired. Further strategies, including the administration of additional vaccine doses and passive immunization with long-acting monoclonal antibodies, might increase protection in this vulnerable patient group.
- Maria Prendecki
- , Michelle Willicombe
- & Stephen P. McAdoo
Nature Reviews Nephrology 17, 790-791
Research Highlights | 15 March 2021

Explaining post-injury T cell death

A recent study in Immunity explains the loss of T cells and consequent increased susceptibility to bacterial infection following severe tissue injury. Injury-induced AIM2 inflammasome activation causes expansion of a CD95L-expressing monocyte population, which leads to extrinsic T cell apoptosis.
- Lucy Bird
Nature Reviews Immunology 21, 205

All News & Comment

Immunosuppression articles from across Nature Portfolio

Latest Research and Reviews

Engineering nanomaterial physical characteristics for cancer immunotherapy

Targeted inhibition of RBPJ transcription complex alleviates the exhaustion of CD8⁺ T cells in hepatocellular carcinoma

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

Biomaterials tools to modulate the tumour microenvironment in immunotherapy

Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells

Tumour-infiltrating lymphocytes: from prognosis to treatment selection

News and Comment

Targeting T cell checkpoints and myeloid suppressor cells is effective in pancreatic cancer

Immunosuppression

Reactivity to type I interferon is key to predict cancer immunotherapy response

Immune regulation in the tumor microenvironment and its relevance in cancer therapy

COVID-19 vaccination in patients with immunity-mediated kidney disease

Explaining post-injury T cell death

Search

Quick links